Get started
CVS HEALTH CORPORATION CEDEAR EACH 15 REP 1 ORDCVS HEALTH CORPORATION CEDEAR EACH 15 REP 1 ORDCVS HEALTH CORPORATION CEDEAR EACH 15 REP 1 ORD

CVS HEALTH CORPORATION CEDEAR EACH 15 REP 1 ORD

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

CVS trade ideas

CVS - DAILY CHART Hi, today we are going to talk about CVS Health Corp and its current landscape. CVS is poised to receive increasing attention from the market as relevant events are taking place. The healthcare company can be benefited from the implied move that Congress will repeal three key Obamacare aspects related to the health industry taxes as part of fiscal 2020 spending bills. News that can boost CVS next year. Thank you for reading and leave your comments if you like. To have access to our exclusive contents, join the Traders Heaven today! Link Below. Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
NYSE:CVS
by Igor-Silva
$CVS Health Bullish but still in downtrend.Bullish run in 2019, but is becoming overbought, despite the gains in 2019 the stock is still in a long term downtrend and we would remains on the sidelines until that channel is broken. There is plenty of upside so need to jump in at the end of the current run, better entries will present themselves. 19.87 P/E ratio, very reasonable. 2.82% yield. Company profile CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise. The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, medical management capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
NYSE:CVS
by Bullishcharts
CVS moment of truth is comingCVS has been headed toward the top of its parallel channel. It's currently overbought, so its first test of the channel top may get rejected. However, expect a breakout soon after. CVS is my favorite investment thesis in the entire market right now. The company is opening 1500 HealthHub stores by the end of 2021 and is also completing a merger with Aetna. Its earnings are expected to grow, and the stock is absurdly undervalued. Fair value based on forward P/E for 2021 is something like $95 per share. Even based on this year's P/E, it should be at least $79. (I base these numbers on the Zack's "Price and Consensus" chart, which is one of my favorite tools for fundamental analysis. We'll do an educational episode on this on the "Wall Street Petting Zoo" Youtube channel next week.)
NYSE:CVSLong
by ChristopherCarrollSmith
CVS Health Corp Stop Heartburn Drug Sales Over Cancer LinksCVS Health Corp (NYSE: CVS), Walgreens Boots Alliance Inc. (NASDAQ: WBA) and Rite Aid Corporation (NYSE: RAD) had mixed fortunes in the market. This is after announcing they will no longer sell a heartburn medication suspected of containing a cancer-causing substance. Zantac is the heartburn medication on the spotlight on the Food and Drug Administration, raising the red flag. Zantac Cancer Links The FDA in a press release has warned that the drug could contain low levels of nitrosamine, an impurity categorized as a human carcinogen. CVS Health stock was up 1.59% while Walgreens stock rallied 1.65% and Rite Aid plunged 4.53% after announcing the withdrawal of Zantac from shelves. Rite Aid has confirmed it is in the process of removing the drug from its shelves as well as other generic version sold under its brand name. Walgreens and CVS have since confirmed that customers would purchase Zantac can return the medication for a refund. However, the companies insist the FDA has not recalled the drug. Novartis AG (NYSE: NVS) is another pharmaceutical company dragged into the ranitidine standoff. The company has also stopped selling a prescription form of ranitidine as it awaits the FDA’s ongoing investigation. GlaxoSmithKline plc. (NYSE: GSK) has also stopped the distribution of a generic version of the drug. Sanofi SA (NASDAQ: SNY), which is the company behind Zantac, was up 0.15% even as the giant pharmaceutical companies announced they would no longer sell the drug. The drugmaker, in its defense, maintains that the levels of contaminants found by the FDA barely exceed the levels found in foods. The environmental contaminant is mostly found in water and foods as well as meats and dairy products. In high levels, the contaminant can trigger tumors in the liver as well as other organs. In humans, they can lead to cancer. FDA Ranitidine And Zantac Probe The FDA is currently investigating a number of ranitidine drugs as well as Zantac on concerns that they contain high levels of nitrosamine impurity that can trigger cancer cells in the human body. The agency is also investigating the possible cause of contamination as well as the potential risk of the impurity to patients. However, the agency is yet to issue an order prohibiting the sale of Zantac drug. Sales suspension by the pharmaceutical giants is thus a precautionary measure awaiting the outcome of the ongoing trials by the agency. “The FDA is not calling for individuals to stop taking ranitidine at this time; however, patients taking prescription ranitidine who wish to discontinue use should talk to their health care professional about other treatment options,” FDA in a statement. Instead of taking Zantac and other OTC ranitidine, the FDC is urging people to take other OTC approved medicines for their conditions. The European Medicines Agency has already joined the FDA in reviewing the drug. Canada, on its part, has stopped the sale of all ranitidine drugs awaiting the ongoing investigations.
NYSE:CVS
by Sector_Reports
CVS Health Corp on verge of Golden Cross===Entry level $60 - Price target $70=== Stock at a juncture, we await a strong buy signal from a golden cross of 50 & 200 MA's. RSI strong but has hit mid channel support and needs a reset. AVERAGE ANALYSTS PRICE TARGET $70 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT P/R RATIO 17 SHORT INTEREST 2% COMPANY PROFILE CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise. The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, medical management capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
NYSE:CVS
by RedHotStocks
CVS attempting rising wedge breakoutCVS has been testing the upper trend line of its rising wedge, which it has breached a couple times in the last two days. The last three days have also seen heavy call option buying activity. CVS has a very bullish 9.4/10 Equity StarMine rating, and it's rated as extremely undervalued by S&P Capital IQ. Investors are betting, in part, that CVS will benefit from the bankruptcy of Fred's, a major competitor. CVS is also now going to be selling a CBD (cannabis) product from SocialCBD. Plus, CVS has big plans to open 50 HealthHUB stores, low-cost clinics that will leverage artificial intelligence as a diagnostic tool. This could help disrupt the cost bubble in the healthcare industry. I don't know that the rising wedge will necessarily break today, but I do think that CVS should see continued strength in the coming year. This is a good long-term buy and hold.
NYSE:CVSLong
by ChristopherCarrollSmith
CVS - finding support at the 200-month simple moving average?Investing idea. Time to exit +/- August 2020. Is the share finding support around 49.65 which is its 200-month simple moving average? The share recently crossed above its 8-month simple moving average. First signal in 8 months and an early indication that internal strength is developing within the share. Bullish Heikin-Ashi trend change. First signal in the last 7 months. The increasing trajectory of the OBV (On-Balance Volume) is supporting a bullish bias. Retracting from RSI oversold territory.
NYSE:CVSLong
by Peet_Serfontein